Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecan
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Neoplasms
Conditions
Triple Negative Breast Neoplasms
Trial Timeline
Dec 21, 2018 → Feb 26, 2027
NCT ID
NCT03742102About Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecan
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecan is a phase 1/2 stage product being developed by AstraZeneca for Triple Negative Breast Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT03742102. Target conditions include Triple Negative Breast Neoplasms.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Neoplasms were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03742102 | Phase 1/2 | Active |
Competing Products
20 competing products in Triple Negative Breast Neoplasms